Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2026 09:06 ET | Source: Medela

Medela Advances Breast Pump Innovation with the Launch of Pump In Style® Pro+ and Freestyle™ Mini Hands-free in Canada

Toronto, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms worldwide and the #1 brand in hospitals1, today announced the Canadian launch of two new innovative...
March 10, 2026 09:05 ET | Source: Medela

Medela Advances Breast Pump Innovation with the Launch of Two Breakthrough Products: Pump In Style® Pro+ and Motion™ InBra

McHenry, Illinois, March 10, 2026 (GLOBE NEWSWIRE) -- Medela, the brand trusted by millions of moms worldwide and the #1 breast pump brand used in hospitals1, today announced the launch of two new...
March 09, 2026 13:37 ET | Source: Ipsen Pharma

Update: Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde

PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les...
March 09, 2026 13:37 ET | Source: Ipsen Pharma

Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision...
March 09, 2026 05:30 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding...
March 09, 2026 02:00 ET | Source: Ipsen Pharma

Ipsen retire volontairement Tazverik® (tazemetostat) dans le traitement du lymphome folliculaire et du sarcome épithélioïde

PARIS, FRANCE, 09 mars 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui le retrait volontaire de Tazverik® (tazemetostat) des marchés où il est commercialisé par Ipsen, et dans toutes les...
March 09, 2026 02:00 ET | Source: Ipsen Pharma

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision...
March 06, 2026 06:30 ET | Source: Bluejay Diagnostics, Inc.

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

ACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests to improve...
March 06, 2026 04:09 ET | Source: Research and Markets

Algorithmic Trading Analysis Report 2026-2035: A $44.34 Billion Market by 2030 with Virtu Financial Inc, IG Group Holdings Plc, FXCM Group, TradeStation Leading

Dublin, March 06, 2026 (GLOBE NEWSWIRE) -- The "Algorithmic Trading Market Report 2026" has been added to ResearchAndMarkets.com's offering. The algorithmic trading market has witnessed...
March 05, 2026 06:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Reports 2025 Full Year Results and Business Updates

— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth — — $457 million net income, driven by profitable core operations and non-core disposal — —...